DTX101
101HEMB01
Phase 2 gene_therapy terminated
Quick answer
DTX101 for Hemophilia B is a Phase 2 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Hemophilia B
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- terminated